MedTrace Logo

AT-001 for Long-term Preservation of Brain Health in Aging

NCT03062384 · Status: COMPLETED · Phase: NA · Type: INTERVENTIONAL · Enrollment: 95

Last updated 2019-08-20

No results posted yet for this study

Summary

The purpose of this study is to evaluate if the use of a yeast-selenium supplement (AT-001) is safe in elderly subjects who do not have dementia, and further, to see if the supplement improves tests that are related to brain health.

Conditions

  • Oxidative Stress

Interventions

DIETARY_SUPPLEMENT

AT-001

DIETARY_SUPPLEMENT

Placebo

Sponsors & Collaborators

  • Alltech Life Sciences Inc.

    collaborator INDUSTRY

  • University of Kentucky

    lead OTHER

Principal Investigators

  • Richard R Murphy, MD · University of Kentucky

  • Ronan Powers, PhD · Alltech Life Sciences Inc.

  • Gregory A. Jicha, MD, PhD · University of Kentucky

Study Design

Allocation
RANDOMIZED
Purpose
PREVENTION
Masking
TRIPLE
Model
PARALLEL

Eligibility

Min Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2016-05-31
Primary Completion
2018-12-31
Completion
2018-12-31

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03062384 on ClinicalTrials.gov